Updates and news related to prostate cancer:
May be effective in preventing certain types of prostate cancer drug resistance
Researchers found that men with a family history of prostate cancer reached the screening risk threshold up to 12 years earlier than the general population.
Men with asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer who are being treated with radium-223 (Xofigo) plus enzalutamide (Xtandi) can reduce their risk of fractures with the use of bone-protecting agents.
The researchers believe their test "could reduce the number of unnecessary prostate cancer biopsies by 32%."
FDA Breakthrough Device Designation Is Granted to Avenda Health for Laser Ablation System in Prostate Cancer
A technology that uses AI to deliver focal laser therapy to prostate tumors was granted breakthrough device designation by the FDA, which will allow for the swift development and commercialization of the product.
Radiopharmaceutical boosts survival
The authors stated that testosterone levels were high with late injections regardless of which therapy was used.
Patients who underwent advanced molecular imaging had higher rates of disease-free survival, according to new research.
Late adverse events indicate need for extended follow-up.
Prostate Radiation Therapy Tied to Improved Survival in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
An article from Us TOO International's newsletter